Benzinga | May 14, 2021 06:26AM EDT

B. Riley Securities Initiates Coverage On Allogene Therapeutics with Buy Rating, Announces Price Target of $52

B. Riley Securities initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Buy rating and announces Price Target of $52.